Clinical Practice Guidelines for Topical NSAIDs in the Treatment of Sports Injuries

Abstract

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat sports injuries, but evidence-based medical guidance for their standardized and rational use is lacking. This guideline working group identified clinically important issues, obtained the full opinions of patients and clinical staff, and discussed them with the expert group. Based on evidence from the literature, the “clinical practice guidelines for topical NSAIDs in the treatment of sports injuries” were formulated following the methods and principles of international guidelines. According to these guidelines, 7 clinical concerns were ultimately selected, and 22 recommendationswere formed. These included the status, indications, contraindications, efficacy, combined application, use in special populations, adverse reactions, and countermeasures of topical NSAIDs in the treatment of sports injuries. The purpose of these guidelines is to provide evidence-based recommendations for practitioners in the fields of orthopedics, sports medicine, rehabilitationmedicine, and sports science, as well as other fields, in the treatment of sports injuries to promote more standardized and rational use of topical NSAIDs.

Keywords

clinical practice guidelines / sports injury / topical NSAIDs

References

[1] Y Yu,“Theoretical System and Policy Thinking of the National Fitness and Healthy China, ” Journal of Beijing Sport University 42, no. 2 (2016):25–35.

[2] W. Zhu and S Chen,“Research Progress of Topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in the Treatment of Musculoskeletal System Pain, ” Chinese Journal of Sports Medicine 35, no. 5 (2016):506–508.

[3] J. A. Paoloni,C. Milne,J. Orchard, and B Hamilton,“Non-steroidal Anti-inflammatory Drugs in Sports Medicine: Guidelines for Practical but Sensible Use, ” British Journal of Sports Medicine 43, no. 11 (2009):863–865.

[4] CSSM. “Chinese Expert Consensus on Topical Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Musculoskeletal System Pain, ” Chinese Medical Frontiers Journal (electronic Edition) 8, no. 7 (2016):24–27.

[5] M. Qu and C Yu. Practical Sports Medicine. Beijing: Peking University Medical Press 2003. 1134.

[6] K. Rae and J Orchard,“The Orchard Sports Injury Classification System (OSICS) Version 10, ” Clinical Journal of Sport Medicine 17, no. 3 (2007):201–204.

[7] S. Chen and H Feng. Modern Orthopedic Sports Medicine. Shanghai: Fudan University Press 2020. 802 p.

[8] T. Timpka,J. Jacobsson,J. Bickenbach,C. F. Finch,J. Ekberg, and L Nordenfelt,“What Is a Sports Injury?” Sports Medicine (Auckland, NZ) 44, no. 4 (2014):423–428.

[9] H. W Mueller-Wohlfahrt,L. Haensel,K. Mithoefer, et al.,“Terminology and Classification of Muscle Injuries in Sport: The Munich Consensus Statement, ” British Journal of Sports Medicine 47, no. 6 (2013):342–350.

[10] A. G. Ross,A. Donaldson, and R. G Poulos,“Nationwide Sports Injury Prevention Strategies: A Scoping Review, ” Scandinavian Journal of Medicine &Science in Sports 31, no. 2 (2021):246–264.

[11] W. van Mechelen,H. Hlobil, and H. C Kemper,“Incidence, Severity, Aetiology and Prevention of Sports Injuries. A Review of Concepts, ” Sports Medicine (Auckland, NZ) 14, no. 2 (1992):82–99.

[12] M Zhou,“History and Prospect of Sports Trauma Rehabilitation in China, ” Chinese Journal of Rehabilitation Medicine 34, no. 8 (2019):885–887.

[13] P. von Rosen,A. Heijne,A. Frohm,C. Fridén, and A Kottorp,“High Injury Burden in Elite Adolescent Athletes: A 52-Week Prospective Study, ” Journal of Athletic Training 53, no. 3 (2018):262–270.

[14] C. H. Moseid,G. Myklebust,M. W. Fagerland,B. Clarsen, and R Bahr,“The Prevalence and Severity of Health Problems in Youth Elite Sports: A 6-Month Prospective Cohort Study of 320 Athletes, ” Scandinavian Journal of Medicine &Science in Sports 28, no. 4 (2018):1412–1423.

[15] A. Flood,G. Waddington,K. Thompson, and S Cathcart,“Increased Conditioned Pain Modulation in Athletes, ” Journal of Sports Sciences 35, no. 11 (2017):1066–1072.

[16] Z. Li,Z. Wan, and Y Liang,“Investigation and Analysis of Sports Injury in Community People’s Amateur Sports Activities, ” Chinese Medical Guide 12, no. 6 (2010):1097–1098.

[17] S. Christopher,B. A. Tadlock,B. J. Veroneau, et al.,“Epidemiological Profile of Pain and Non-Steroid Anti-Inflammatory Drug Use in Collegiate Athletes in the United States, ” BMC Musculoskeletal Disorders [Electronic Resource] 21, no. 1 (2020):561.

[18] D. J. Hunter and S Bierma-Zeinstra,“Osteoarthritis, ” Lancet 393, no. 10182 (2019):1745–1759.

[19] Joint Surgery Branch of the Chinese Orthopaedic Association,Chinese Orthopedic Association. “Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2021 edition), ” Chinese Journal of Orthopedics 41, no. 18 (2021):1291–1314.

[20] A. Cui,H. Li,D. Wang,J. Zhong,Y. Chen, and H Lu,“Global, Regional Prevalence, Incidence and Risk Factors of Knee Osteoarthritis in Population-Based Studies, ” EClinicalMedicine 29-30, (2020):100587.

[21] C. L. Feucht and D. R Patel,“Analgesics and Anti-Inflammatory Medications in Sports: Use and Abuse, ” Pediatric Clinics of North America 57, no. 3 (2010):751–774.

[22] A. K. Shah,G. Wei,R. C. Lanman,V. O. Bhargava, and S. J Weir,“Percutaneous Absorption of Ketoprofen From Different Anatomical Sites in Man, ” Pharmaceutical Research 13, no. 1 (1996):168–172.

[23] J. M Weiler,“Medical Modifiers of Sports Injury. The Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Sports Soft-Tissue Injury, ” Clinics in Sports Medicine 11, no. 3 (1992):625–644.

[24] S. Derry,P. J. Wiffen,E. A. Kalso, et al.,“Topical Analgesics for Acute and Chronic Pain in Adults—An Overview of Cochrane Reviews, ” Cochrane Database of Systematic Reviews (Online) 5, no. 5 (2017): Cd008609.

[25] D. C. Warner,G. Schnepf,M. S. Barrett,D. Dian, and N. L Swigonski,“Prevalence, Attitudes, and Behaviors Related to the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Student Athletes, ” The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 30, no. 3 (2002):150–153.

[26] N. Holmes,P. F. Cronholm,A. J. Duffy 3rd, and D Webner,“Nonsteroidal Anti-Inflammatory Drug Use in Collegiate Football Players, ” Clinical Journal of Sport Medicine 23, no. 4 (2013):283–286.

[27] M. L. McPherson and N. M Cimino,“Topical NSAID Formulations, ” Pain Medicine (Malden, Mass.) 14, no. Suppl 1 (2013): S35–39.

[28] B. S Galer,“All Topical NSAIDs Not Created Equal–Understanding Topical Analgesic Drug Formulations, ” Pain 139, no. 1 (2008):237–238.

[29] E. Choi,F. S. Nahm,W. K. Han,P. B. Lee, and J Jo,“Topical Agents: A Thoughtful Choice for Multimodal Analgesia, ” Korean Journal of Anesthesiology 73, no. 5 (2020):384–393.

[30] T. Gorski,E. L. Cadore,S. S. Pinto, et al.,“Use of NSAIDs in Triathletes: Prevalence, Level of Awareness and Reasons for Use, ” British Journal of Sports Medicine 45, no. 2 (2011):85–90.

[31] C. Zeng,M. Doherty,M. S. M. Persson, et al.,“Comparative Efficacy and Safety of Acetaminophen, Topical and Oral Non-Steroidal Anti-Inflammatory Drugs for Knee Osteoarthritis: Evidence From a Network Meta-Analysis of Randomized Controlled Trials and Real-World Data, ” Osteoarthritis and Cartilage 29, no. 9 (2021):1242–1251.

[32] M. S. Roberts,H. S. Cheruvu,S. E. Mangion, et al.,“Topical Drug Delivery: History, Percutaneous Absorption, and Product Development, ” Advanced Drug Delivery Reviews 177, no. (2021):113929.

[33] E. Beetge,J. du Plessis,D. G. Müller,C. Goosen, and F. J van Rensburg,“The Influence of the Physicochemical Characteristics and Pharmacokinetic Properties of Selected NSAID’s on Their Transdermal Absorption, ” International Journal of Pharmaceutics 193, no. 2 (2000):261–264.

[34] W. Leppert,M. Malec-Milewska,R. Zajaczkowska, and J Wordliczek,“Transdermal and Topical Drug Administration in the Treatment of Pain, ” Molecules (Basel, Switzerland) 23, no. 3 (2018):681.

[35] J. L. Kienzler,M. Gold, and F Nollevaux,“Systemic Bioavailability of Topical Diclofenac Sodium Gel 1%Versus Oral Diclofenac Sodium in Healthy Volunteers, ” Journal of Clinical Pharmacology 50, no. 1 (2010):50–61.

[36] M. Hagenand M Baker,“Skin Penetration and Tissue Permeation After Topical Administration of Diclofenac, ” Current Medical Research and Opinion 33, no. 9 (2017):1623–1634.

[37] A. Figueras,D. Capellà,J. M. Castel, and J. R Laorte,“Spontaneous Reporting of Adverse Drug Reactions to Non-steroidal Anti-inflammatory Drugs. A Report From the Spanish System of Pharmacovigilance, Including an Early Analysis of Topical and Enteric-Coated Formulations, ” European Journal of Clinical Pharmacology 47, no. 4 (1994):297–303.

[38] F. Rannou,J. P. Pelletier, and J Martel-Pelletier,“Efficacy and Safety of Topical NSAIDs in the Management of Osteoarthritis: Evidence From Real-Life Setting Trials and Surveys, ” Seminars in Arthritis and Rheumatism 45, no. 4 Suppl (2016): S18–21.

[39] R. L Barkin,“Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome, ” American Journal of Therapeutics 22, no. 5 (2015):388–407.

[40] R. L. Diaz,J. Gardeazabal,P. Manrique, et al.,“Greater Allergenicity of Topical Ketoprofen in Contact Dermatitis Confirmed by Use, ” Contact Dermatitis 54, no. 5 (2006):239–243.

[41] C. Plaza-Serón Mdel,P. Ayuso,N. Pérez-Sánchez, et al.,“Copy Number Variation in ALOX5 and PTGER1 Is Associated With NSAIDs-Induced Urticaria and/or Angioedema, ” Pharmacogenetics and Genomics 26, no. 6 (2016):280–287.

[42] T. M. Laidlawand K. N Cahill,“Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs, ” The Journal of Allergy and Clinical Immunology In Practice 5, no. 3 (2017):537–545.

[43] G. L. Sitenga,E. B. Ing,R. G. Van Dellen,B. R. Younge, and J. A Leavitt,“Asthma Caused by Topical Application of Ketorolac, ” Ophthalmology 103, no. 6 (1996):890–892.

[44] Y. Chen,K. Yang, and X Wang,“Guidelines for Formulating/Revising Clinical Guidelines in China (2022 edition), ” Chinese Medical Journal 102, no. 10 (2022):697–703.

[45] G. Guyatt,A. D. Oxman,E. A. Akl, et al.,“GRADE Guidelines:1. Introduction-GRADE Evidence Profiles and Summary of Findings Tables, ” Journal of Clinical Epidemiology 64, no. 4 (2011):383–394.

[46] Y. Chen,K. Yang,A. Marušic, et al.,“A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement, ” Annals of Internal Medicine 166, no. 2 (2017):128–132.

[47] X. Huang,J. Lin, and D Demner-Fushman,“Evaluation of PICO as a Knowledge Representation for Clinical Questions, ” AMIA Annual Symposium Proceedings AMIA Symposium 2006 (2006):359–363.

[48] I. R. Diamond,R. C. Grant,B. M. Feldman, et al.,“Defining Consensus: A Systematic Review Recommends Methodologic Criteria for Reporting of Delphi Studies, ” Journal of Clinical Epidemiology 67, no. 4 (2014):401–409.

[49] S. Derry,R. A. Moore,H. Gaskell,M. McIntyre, and P. J Wiffen,“Topical NSAIDs for Acute Musculoskeletal Pain in Adults, ” Cochrane Database of Systematic Reviews (Online) 2015, no. 6 (2015): Cd007402.

[50] S. Derry,P. Conaghan,J. A. Da Silva,P. J. Wiffen, and R. A Moore,“Topical NSAIDs for Chronic Musculoskeletal Pain in Adults, ” Cochrane Database of Systematic Reviews (Online) 4, no. 4 (2016): Cd007400.

[51] Z. H. Deng,C. Zeng,Y. Yang, et al.,“Topical Diclofenac Therapy for Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials, ” Clinical Rheumatology 35, no. 5 (2016):1253–1261.

[52] C. Zeng,J. Wei,M. S. M. Persson, et al.,“Relative Efficacy and Safety of Topical Non-steroidal Anti-inflammatory Drugs for Osteoarthritis: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials and Observational Studies, ” British Journal of Sports Medicine 52, no. 10 (2018):642–650.

[53] R. Mu,C. D. Bao,Z. W. Chen, et al.,“Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Knee Osteoarthritis: A Randomized Controlled Non-inferiority Trial, ” Clinical Rheumatology 35, no. 1 (2016):165–173.

[54] R. D. Altman,R. L. Dreiser,C. L. Fisher,W. F. Chase,D. S. Dreher, and J Zacher,“Diclofenac Sodium Gel in Patients With Primary Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial, ” The Journal of Rheumatology 36, no. 9 (2009):1991–1999.

[55] R. R. Bannuru,M. C. Osani,E. E. Vaysbrot, et al.,“OARSI Guidelines for the Non-surgical Management of Knee, Hip, and Polyarticular Osteoarthritis, ” Osteoarthritis and Cartilage 27, no. 11 (2019):1578–1589.

[56] A. Abdulla,N. Adams,M. Bone, et al.,“Guidance on the Management of Pain in Older People, ” Age and Ageing 42 Suppl 1 (2013): i1–57.

[57] S. L. Kolasinski,T. Neogi,M. C. Hochberg, et al.,“2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee, ” Arthritis Care &Research 72, no. 2 (2020):149–162.

[58] O. Bruyère,G. Honvo,N. Veronese, et al.,“An Updated Algorithm Recommendation for the Management of Knee Osteoarthritis From the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), ” Seminars in Arthritis and Rheumatism 49, no. 3 (2019):337–350.

[59] N. K. Arden,T. A. Perry,R. R. Bannuru, et al.,“Non-Surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines, ” Nature Reviews Rheumatology 17, no. 1 (2021):59–66.

[60] B. S. Rafanan Jr.,B. F. Valdecañas,B. P. Lim, et al.,“Consensus Recommendations for Managing Osteoarthritic Pain With Topical NSAIDs in Asia-Pacific, ” Pain Management 8, no. 2 (2018):115–128.

[61] P. J. Wiffenand J Xia,“Systematic Review of Topical Diclofenac for the Treatment of Acute and Chronic Musculoskeletal Pain, ” Current Medical Research and Opinion 36, no. 4 (2020):637–650.

[62] M. Serinken,C. Eken,K. Tunay, and Y Golcuk,“Ketoprofen Gel Improves Low Back Pain in Addition to IV Dexketoprofen: A Randomized Placebo-Controlled Trial, ” The American Journal of Emergency Medicine 34, no. 8 (2016):1458–1461.

[63] H. G. Predel,B. Giannetti,H. Pabst,A. Schaefer,A. M. Hug, and I Burnett,“Efficacy and Safety of Diclofenac Diethylamine 1.16%Gel in Acute Neck Pain: A Randomized, Double-Blind, Placebo-Controlled Study, ” BMC Musculoskeletal Disorders [Electronic Resource] 14, (2013):250.

[64] M. P. J. van den Bekerom,A. Sjer,M. P. Somford,G. H. Bulstra,P. A. A. Struijs, and G Kerkhoffs,“Non-steroidal Anti-inflammatory Drugs (NSAIDs) for Treating Acute Ankle Sprains in Adults: Benefits Outweigh Adverse Events, ” Knee Surgery, Sports Traumatology, Arthroscopy 23, no. 8 (2015):2390–2399.

[65] M. Serinken,C. Eken, and H Elicabuk,“Topical Ketoprofen Versus Placebo in Treatment of Acute Ankle Sprain in the Emergency Department, ” Foot &Ankle International 37, no. 9 (2016):989–993.

[66] G. Vuurberg,A. Hoorntje,L. M. Wink, et al.,“Diagnosis, Treatment and Prevention of Ankle Sprains: Update of an Evidence-Based Clinical Guideline, ” British Journal of Sports Medicine 52, no. 15 (2018):956.

[67] G. Spacca,A. Cacchio,A. Forgács,P. Monteforte, and G Rovetta,“Analgesic Efficacy of a Lecithin-Vehiculated Diclofenac Epolamine Gel in Shoulder Periarthritis and Lateral Epicondylitis: A Placebo-Controlled, Multicenter, Randomized, Double-Blind Clinical Trial, ” Drugs Under Experimental and Clinical Research 31, no. 4 (2005):147–154.

[68] P. Pattanittum,T. Turner,S. Green, and R Buchbinder,“Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Treating Lateral Elbow Pain in Adults, ” Cochrane Database of Systematic Reviews (Online) 2013, no. 5 (2013): Cd003686.

[69] R. Burnham,R. Gregg,P. Healy, and R Steadward,“The Effectiveness of Topical Diclofenac for Lateral Epicondylitis, ” Clinical Journal of Sport Medicine 8, no. 2 (1998):78–81.

[70] J. J. May,G. Lovell, and W. G Hopkins,“Effectiveness of 1%Diclofenac Gel in the Treatment of Wrist Extensor Tenosynovitis in Long Distance Kayakers, ” Journal of Science And Medicine In Sport 10, no. 1 (2007):59–65.

[71] B. Mazières,S. Rouanet,Y. Guillon,C. Scarsi, and V Reiner,“Topical Ketoprofen Patch in the Treatment of Tendinitis: A Randomized, Double Blind, Placebo Controlled Study, ” The Journal of Rheumatology 32, no. 8 (2005):1563–1570.

[72] F. Ginsbergand J. P Famaey,“Double-Blind, Randomized Crossover Study of the Percutaneous Efficacy and Tolerability of a Topical Indomethacin Spray Versus Placebo in the Treatment of Tendinitis, ” The Journal of International Medical Research 19, no. 2 (1991):131–136.

[73] E. Bussin,B. Cairns,T. Gerschman,M. Fredericson,J. Bovard, and A Scott,“Topical Diclofenac vs Placebo for the Treatment of Chronic Achilles Tendinopathy: A Randomized Controlled Clinical Trial, ” PLoS ONE 16, no. 3 (2021): e0247663.

[74] T. Jurca,L. Jozsa,R. Suciu, et al.,“Formulation of Topical Dosage Forms Containing Synthetic and Natural Anti-Inflammatory Agents for the Treatment of Rheumatoid Arthritis, ” Molecules (Basel, Switzerland) 26, no. 1 (2020):24.

[75] N. Nagai,C. Yoshioka, and Y Ito,“Topical Therapies for Rheumatoid Arthritis by Gel Ointments Containing Indomethacin Nanoparticles in Adjuvant-Induced Arthritis Rat, ” Journal of Oleo Science 64, no. 3 (2015):337–346.

[76] C. Rolf,B. Engström,C. Beauchard, and L. D. Jacobs,“Le Liboux A. Intra-Articular Absorption and Distribution of Ketoprofen After Topical Plaster Application and Oral Intake in 100 Patients Undergoing Knee Arthroscopy, ” Rheumatology 38, no. 6 (1999):564–567.

[77] K. A. Bukhari,I. A. Khan,S. Ishaq, et al.,“Formulation and Evaluation of Diclofenac Potassium Gel in Sports Injuries With and Without Phonophoresis, ” Gels (Basel, Switzerland) 8, no. 10 (2022):612.

[78] B. Cagnie,E. Vinck,S. Rimbaut, and G Vanderstraeten,“Phonophoresis versus Topical Application of Ketoprofen: Comparison Between Tissue and Plasma Levels, ” Physical Therapy 83, no. 8 (2003):707–712.

[79] D. Wetzel,W. Menke,R. Dieter,V. Smasal,B. Giannetti, and M Bulitta,“Escin/Diethylammonium Salicylate/Heparin Combination Gels for the Topical Treatment of Acute Impact Injuries: A Randomised, Double Blind, Placebo Controlled, Multicentre Study, ” British Journal of Sports Medicine 36, no. 3 (2002):183–188.

[80] V. Sethi,L. Van der Laan,S. Gupta, and K. C Piros,“Perspectives of Healthcare Professionals Towards Combination Use of Oral Paracetamol and Topical Non-Steroidal Inflammatory Drugs in Managing Mild-to-Moderate Pain for Osteoarthritis in a Clinical Setting: An Exploratory Study, ” J Pain Res 15, (2022):2263–2272.

[81] V. Sethi,L. Qin,E. Cox,I. F. Trocóniz, and O Della Pasqua,“Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain?, ” Pain and Therapy 13, no. 1 (2024):145–159.

[82] M. Serinken,C. Eken,K. Tünay, and Y Gölcük,“Topical Ketoprofen Versus Placebo in Children Presenting with Ankle Sprain to the Emergency Department: A Randomized Controlled Study, ” Pediatric Emergency Care 36, no. 8 (2020): e447–e450.

[83] M. Underwood,D. Ashby,D. Carnes, et al.,“Topical or Oral Ibuprofen for Chronic Knee Pain in Older People. The TOIB Study, ” Health Technology Assessment (Winchester, England) 12, no. 22 (2008): iii–iv,ix–155.

[84] M. Underwood,D. Ashby,P. Cross, et al.,“Advice to Use Topical or Oral Ibuprofen for Chronic Knee Pain in Older People: Randomised Controlled Trial and Patient Preference Study, ” Bmj 336, no. 7636 (2008):138–142.

[85] U. E. Makris,M. J. Kohler, and L Fraenkel,“Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults With Osteoarthritis: A Systematic Literature Review, ” The Journal of Rheumatology 37, no. 6 (2010):1236–1243.

[86] D. Carnes,Y. Anwer,M. Underwood,G. Harding, and S Parsons,“Influences on Older People’s Decision Making Regarding Choice of Topical or Oral NSAIDs for Knee Pain: Qualitative Study, ” Bmj 336, no. 7636 (2008):142–145.

[87] G. Klinger,B. Stahl,P. Fusar-Poli, and P Merlob,“Antipsychotic Drugs and Breastfeeding, ” Pediatric Endocrinology Reviews: PER 10, no. 3 (2013):308–317.

[88] M. Bloor and M Paech,“Nonsteroidal Anti-inflammatory Drugs During Pregnancy and the Initiation of Lactation, ” Anesthesia and Analgesia 116, no. 5 (2013):1063–1075.

[89] J. M. Evans,A. D. McMahon,M. M. McGilchrist, et al.,“Topical Non-Steroidal Anti-inflammatory Drugs and Admission to Hospital for Upper Gastrointestinal Bleeding and Perforation: A Record Linkage Case-Control Study, ” Bmj 311, no. 6996 (1995):22–26.

[90] A. M. Schjerning,P. McGettigan, and G Gislason,“Cardiovascular Effects and Safety of (Non-Aspirin) NSAIDs, ” Nature Reviews Cardiology 17, no. 9 (2020):574–584.

[91] T. C. Lin,D. H. Solomon,S. K. Tedeschi,K. Yoshida, and Y. H Kao Yang,“Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients with Rheumatoid Arthritis, ” Journal of the American Heart Association 6, no. 11 (2017): e006874.

[92] T. Delungahawatta,A. Pokharel,R. Paz, and C. J Haas,“Topical Diclofenac-Induced Hepatotoxicity, ” Journal of Community Hospital Internal Medicine Perspectives 13, no. 3 (2023):108–112.

[93] F. J. de Abajo,D. Montero,M. Madurga, and L. A García Rodríguez,“Acute and Clinically Relevant Drug-induced Liver Injury: A Population Based Case-Control Study, ” British Journal of Clinical Pharmacology 58, no. 1 (2004):71–80.

[94] T. Katsuno,K. Togo,N. Ebata, et al.,“Burden of Renal Events Associated With Nonsteroidal Anti-inflammatory Drugs in Patients With Osteoarthritis and Chronic Low Back Pain: A Retrospective Database Study, ” Pain and Therapy 10, no. 1 (2021):443–455.

[95] P. A. Andrews and S. A Sampson,“Topical Non-steroidal Drugs Are Systemically Absorbed and May Cause Renal Disease, ” Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association 14, no. 1 (1999):187–189.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.